Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Protokinetix Inc

Company price
0.002 USD 0.00(0%)
Last update at 2026-11-17T21:00:00Z
VOLUME
2962
Market Cap
0.08M

Momentum Score

…

ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). Its AFGPs are used in various commercial applications, such as targeted health care solutions, as well as AAGPs are used in ophthalmology, dermatology, transplants, and biomanufacturing areas. The company was formerly known as RJV Network, Inc. and changed its name to ProtoKinetix, Incorporated in July 2003. ProtoKinetix, Incorporated was incorporated in 1999 and is based in Dalton, Ohio.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.01
High
52 Week Price Range
0.00
Low
0.01
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-123.01%
Net Debt
0.00M
ROCE
-132.12%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -0.39M -0.36M -0.41M -1.91M -2.33M
Net income -0.39M -0.36M -0.41M -1.91M -2.33M
Selling general administrative 0.24M 0.21M 0.25M 1.40M 1.89M
Selling and marketing expenses - - 0.25M - -
Gross profit - -0.05M -0.05M - -
Reconciled depreciation 0.05M 0.05M 0.05M 0.06M 0.00M
Ebit - -0.36M -0.42M -1.91M -2.33M
Ebitda - -0.31M -0.37M -1.85M -2.33M
Depreciation and amortization - 0.05M 0.05M - -
Operating income -0.39M -0.31M -0.37M -1.91M -2.33M
Other operating expenses - 0.36M 0.42M - -
Interest expense - - - - 0.00M
Income tax expense - - 0.00M - -
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 0.39M 0.31M 0.37M 1.91M 2.33M
Cost of revenue - 0.05M 0.05M - -
Total other income expense net - -0.05M -0.05M - -
Net income from continuing ops -0.39M -0.36M -0.42M -1.91M -2.33M
Net income applicable to common shares - - - -1.91M -2.33M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 0.48M 0.47M 0.48M 0.46M 0.45M
Intangible assets 0.48M 0.47M 0.46M 0.44M 0.36M
Other current assets - 0.00M 0.00M 0.00M 0.03M
Total liab 0.19M 0.12M 0.04M 0.04M 0.09M
Total stockholder equity 0.30M 0.34M 0.44M 0.42M 0.35M
Other current liab - 0.12M 0.04M - -
Common stock - 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -48.62M -48.23M -47.86M -47.45M -45.54M
Other assets - - 0.00M - -
Cash 0.00M -0.00M 0.02M 0.03M 0.06M
Total current liabilities 0.19M 0.12M 0.04M 0.04M 0.09M
Net debt - 0.00M -0.02M - -
Other stockholder equity - 48.57M 48.30M - -
Total current assets 0.00M -0.00M 0.02M 0.03M 0.08M
Net tangible assets - - - -0.01M -0.01M
Accounts payable - 0.12M 0.00M 0.04M 0.09M
Accumulated other comprehensive income - - 0.00M - -
Non current assets total 0.48M 0.47M 0.46M 0.44M 0.36M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.06M -0.06M -0.13M -0.09M
Change to liabilities - - - -0.05M 0.05M
Total cashflows from investing activities - -0.06M -0.06M -0.13M -0.09M
Total cash from financing activities 0.20M 0.26M 0.43M 0.90M 0.84M
Change to operating activities - - - 0.02M -0.02M
Net income -0.39M -0.36M -0.42M -1.91M -2.33M
Change in cash 0.01M -0.03M -0.01M -0.03M -0.14M
Begin period cash flow -0.00M 0.02M 0.03M 0.06M 0.19M
End period cash flow 0.00M -0.00M 0.02M 0.03M 0.06M
Total cash from operating activities -0.14M -0.22M -0.38M -0.80M -0.89M
Issuance of capital stock 0.20M 0.26M 0.43M 0.90M 0.84M
Depreciation 0.05M 0.05M 0.05M 0.06M 0.00M
Other cashflows from investing activities - -0.06M -0.06M - -
Other cashflows from financing activities - 0.26M -0.06M - -
Change to netincome - - - 1.07M 1.41M
Capital expenditures 0.06M 0.06M 0.06M 0.13M 0.09M
Change in working capital 0.21M 0.08M -0.01M -0.03M 0.02M
Stock based compensation 0.00M 0.01M 0.00M 1.07M 1.41M
Other non cash items - 0.01M -0.00M - -
Free cash flow -0.19M -0.22M -0.44M -0.94M -0.98M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PKTX
Protokinetix Inc
-
-%
0.00 - - 3659.96 0.28 70571.47 -4.82
NVO
Novo Nordisk A/S
-1.25
3.07%
39.45 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-
-%
536.45 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-9.75
1.02%
948.01 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Protokinetix Inc

ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). Its AFGPs are used in various commercial applications, such as targeted health care solutions, as well as AAGPs are used in ophthalmology, dermatology, transplants, and biomanufacturing areas. The company was formerly known as RJV Network, Inc. and changed its name to ProtoKinetix, Incorporated in July 2003. ProtoKinetix, Incorporated was incorporated in 1999 and is based in Dalton, Ohio.

109 W Main St, Dalton, OH, United States, 44618

330 455 4971

Name Title Year Born
Mr. Clarence Edward Smith Chairman, CEO & Pres 1964
Mr. Michael Richard Guzzetta CPA Chief Financial Officer 1958
Dr. Jean-Charles Quirion Ph.D. Head of Researchers for Rouen NA
Mr. Michael Richard Guzzetta CPA Chairman, CEO, CFO, Treasurer & Secretary 1958
Dr. Keith R. Brunt Ph.D. President & Director 1979

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…